Patients with unilateral cataract find it easier to perform near and distance activities than bilateral patients.
Patients with unilateral cataract find it easier to perform near and distance activities than bilateral patients, reveals a study in the Journal of Paediatric Ophthalmology and Strabismus.
Dr Caitriona Kirwan et al., Children's University Hospital, University College, Dublin, Ireland, conducted a retrospective chart review on 16 patients with a history of unilateral cataract and 22 patients with bilateral cataract. Each patient previously underwent surgery when aged 24 months of younger.
Patients aged 13 years or older were selected to partake in the study and educational performance was assessed. There was also a control group of 15 healthy participants with no visual complaints. All volunteers completed a questionnaire.
The bilateral cataract group found it harder to perform near and distance activities compared to the unilateral group. The bilateral group also had significantly lower vision-specific social functioning, role difficulties, mental health, and composite scores.
However, between the unilateral and bilateral groups there was no significant difference in ocular pain, vision-specific social functioning, role difficulties and dependency scores.
Both groups were comparable with regards to general vision scores, but the unilateral cataract group found it easier to perform near and distance activities and specific vision tasks.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.